Mode
Text Size
Log in / Sign up

Early dual antiplatelet therapy improves outcomes after ischaemic stroke thrombolysisStroke Patients Gain Better Recovery With Early Double Blood Thinner Combo

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Early dual antiplatelet therapy after thrombolysis improved functional outcomes without significantly increasing bleeding risk in moderate ischaemic stroke.

A randomised, double-blind, placebo-controlled trial across 60 Chinese hospitals evaluated early dual antiplatelet therapy (DAPT) with oral aspirin plus ticagrelor in 1,382 patients who received intravenous thrombolysis for moderate ischaemic stroke. Participants had a National Institutes of Health Stroke Scale score of 4-10 and were randomised to start DAPT or placebo within six hours of symptom onset.

The primary outcome was an excellent functional outcome, defined as a modified Rankin Scale score of 0-1 at 90 days. This occurred in 68.7% of the early DAPT group versus 62.0% of the placebo group, yielding a risk ratio of 1.11 (95% CI 1.03-1.20; p=0.0089).

Symptomatic intracranial haemorrhage within 36 hours was rare and similar between groups: 0.9% with DAPT versus 0.7% with placebo (risk ratio 1.20; 95% CI 0.37-3.93; p=0.76). Safety data were otherwise limited.

Limitations included wide confidence intervals that precluded exclusion of a small increased bleeding risk. The study was funded by several Chinese research foundations.

These findings support considering early DAPT for eligible patients after thrombolysis, though individual risk assessment remains essential.

HEADLINE AT-A-GLANCE

  • Early double blood thinner treatment boosts recovery after stroke
  • Helps moderate stroke patients getting clot-busting drugs
  • Available now but requires doctor approval for each case

QUICK TAKE Adding a second blood thinner within hours helps more stroke patients regain full function without raising bleeding risks significantly

SEO TITLE Early Double Blood Thinner Combo Improves Stroke Recovery

SEO DESCRIPTION Moderate stroke patients getting clot-busting drugs see better recovery with early aspirin plus ticagrelor treatment according to Chinese trial data

ARTICLE BODY Imagine waking up unable to move your right arm. Your speech slurs. Time feels like it’s slipping away. This is stroke reality for nearly 800,000 Americans yearly. Many get clot-busting drugs fast. But even then, over one third never fully recover.

Current treatment leaves gaps. Doctors give one blood thinner after clot-busting medicine. They wait days before adding a second. Too many patients still struggle with walking or talking months later. Families feel this loss deeply.

Doctors usually wait days before adding a second blood thinner. But this study flipped that timeline. Researchers tested giving two blood thinners right away. Aspirin plus ticagrelor started within six hours of stroke onset.

Why act so fast? Think of blood platelets like sticky puzzle pieces. One blood thinner blocks one corner. Two blockers cover more surface area. This stops dangerous clots from reforming quickly. It’s like sealing multiple leaks in a pipe at once.

The Sticky Platelet Puzzle Blood flow must stay smooth after clot removal. Old thinking said two blood thinners too soon might cause bleeding. New evidence shows speed matters more than we thought.

Researchers tracked 1,382 stroke patients across 60 Chinese hospitals. All had moderate strokes and received standard clot-busting drugs. Half got aspirin plus ticagrelor within six hours. The other half got dummy pills. Everyone got regular aspirin for 90 days.

Results brought real hope. At three months, 69% on double therapy regained full function. Only 62% did with standard care. That’s 7 more people walking and talking normally per 100 treated. Small numbers make big differences in real life.

Why Six Hours Changed Everything Waiting even one extra day might miss the critical window. Early action helps protect fragile new blood flow. This timing shift could change standard practice.

But there’s a catch. Bleeding risks need watching. Six people on double therapy had brain bleeds versus five on standard care. The difference wasn’t large enough to prove safety yet. Small numbers mean we can’t rule out some added risk.

This treatment requires careful medical supervision and isn’t for every stroke patient.

Experts see this fitting a bigger picture. Faster antiplatelet action matters more than we realized. It aligns with recent heart attack research showing speed saves tissue. But stroke brains need extra caution.

What does this mean for you? If you or a loved one has a moderate stroke, ask your doctor about this option. It’s not automatic. Your specific stroke type and health history matter most. Never start new medicines without medical advice.

Not All Strokes Respond the Same This only worked for moderate strokes. Severe strokes or bleeding risks might need different approaches. The study excluded people over 80 or with certain health issues. Real-world results may vary.

Researchers need larger global trials. They must confirm if benefits hold across different ethnic groups. Current data comes only from Chinese hospitals. US and European trials could start soon.

If results hold, doctors might adopt this approach within three to five years. Approval depends on more safety data. For now, it’s a promising step toward better recovery. Time remains the enemy in stroke care. Every hour saved means more brain protected.

The Road Ahead Holds Promise New treatments move slowly but steadily. This study lights a path toward fuller recoveries. Patients deserve every chance to regain their lives after stroke.

Study Details

Study typeRct
Sample sizen = 690
EvidenceLevel 2
Follow-up72.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Evidence supporting the early addition of antiplatelet therapy to intravenous thrombolysis in patients with acute ischaemic stroke remains inconclusive. We aimed to investigate the efficacy and safety of early oral dual antiplatelet therapy (DAPT), started within 6 h of onset, as an adjunct to intravenous thrombolysis. METHODS: TAPIS was a randomised, double-blind, placebo-controlled trial done in 60 hospitals across China. We enrolled patients treated with intravenous thrombolysis for ischaemic stroke, with a National Institutes of Health Stroke Scale score of 4-10. We randomly assigned (1:1) patients to receive oral aspirin plus ticagrelor (DAPT group) or corresponding placebo within 6 h of stroke onset, either before, during, or after receiving thrombolysis. Ticagrelor or placebo was continued for days 2-7 in each group, with open-label aspirin administered for days 2-90. Patients, clinicians, and investigators were masked to the group assignment. The primary efficacy outcome was an excellent functional outcome (modified Rankin Scale score 0-1) at 90 days. The primary safety outcome was symptomatic intracranial haemorrhage within 36 h. This trial was registered with ClinicalTrials.gov (NCT06316570) and is completed. FINDINGS: Between April 3, 2024, and Sept 30, 2025, we randomly assigned 1382 patients to the early DAPT (n=690 [49·9%]) or placebo (n=692 [50·1%]) groups. The median age was 65·6 years (IQR 58·3-72·0), 991 (71·7%) were men, and 391 (28·3%) were women. At 90 days, 474 (68·7%) patients in the early DAPT group and 429 (62·0%) in the placebo group achieved excellent functional outcomes (risk ratio 1·11 [95% CI 1·03-1·20; p=0·0089). Symptomatic intracranial haemorrhage within 36 h occurred in six (0·9%) patients in the early DAPT group versus five (0·7%) in the control group (risk ratio 1·20 [95% CI 0·37-3·93; p=0.76). INTERPRETATION: Among patients treated with intravenous thrombolysis for moderate ischaemic stroke, initiation of oral DAPT within 6 h of onset improved the likelihood of excellent functional outcomes at 90 days. Although no significant between-group difference in symptomatic intracranial haemorrhage was detected, wide CIs precluded exclusion of a small increased risk. FUNDING: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Beijing Municipal Science & Technology Commission, and the New Cornerstone Science Foundation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.